KRAS and non-small cell lung carcinoma: Sotorasib (AMG 510), a small molecule-targeted therapeutic that selectively inhibits the KRAS protein with the G12C mutation [8], is already approved by the regulatory authorities for the treatment of patients with KRAS G12C-mutated non-small-cell lung cancer [9].